Fed. Circ. Won't Halt Gilenya Generics During Novartis Appeal
The Federal Circuit on Tuesday declined Novartis Pharmaceuticals' request to stay the mandate in the court's recent decision that the patent covering multibillion-dollar multiple sclerosis drug Gilenya is invalid while the...To view the full article, register now.
Already a subscriber? Click here to view full article